T1	intervention 73 109	adjuvant chemotherapy plus goserelin
T2	control 131 144	therapy alone
T3	eligibility 149 204	premenopausal patients with node-negative breast cancer
T5	total-participants 536 540	1063
T6	intervention-participants 610 613	346
T7	control-participants 719 722	360
T8	intervention-participants 799 802	357
T10	outcome 1075 1102	disease-free survival (DFS)
T12	iv-bin-percent 1174 1177	68%
T13	cv-bin-percent 1148 1151	69%
T14	iv-bin-percent 1118 1121	77%
T15	outcome 988 1007	ER-positive cohort,
T16	outcome 1272 1290	ER-negative tumors
T18	outcome 1332 1335	DFS
T19	cv-bin-percent 1355 1358	67%
T20	iv-bin-percent 1389 1392	69%
T21	cv-bin-percent 1439 1442	61%
T4	outcome 1337 1348	12-year DFS
T11	outcome 1104 1115	12-year DFS
